Charities fund new clinical trial
Solving Kids’ Cancer, with Neuroblastoma UK, has awarded a grant of £609,762.40 to enable the SIOPEN High-Risk Neuroblastoma Clinical Trial 2 (HR-NBL2) to open in the UK, it is anticipated to open in early 2021.
Research update - May 2020
The coronavirus pandemic has brought new challenges to our ongoing research programme, as we work with experts worldwide to bring more, better and less toxic treatment to children in the UK and beyond.
Watch brave Kira on Scotland Tonight
Kira Noble, supported by Solving Kids' Cancer throughout her cancer journey, appeared on Scotland Tonight on 13th February as STV followed her latest scan and results.
Grant awarded to identify markers of poor survival in high-risk neuroblastoma
Solving Kids’ Cancer Europe, Solving Kids' Cancer in New York, Oscar Knox Fund, Smiles for Stanley Fund and Merryn Lacy Trust have awarded a grant of $420,000.
Outcome for children in the UK after high-risk neuroblastoma treatment
We explain the recent statement from the UK clinical community.
CCLG statement: Outcome after high-risk neuroblastoma treatment
SIOPEN, the UK National Cancer Research Institute Neuroblastoma Group and the CCLG Neuroblastoma Special Interest Group are committed to further improving the outcome for children with neuroblastoma.
BEACON study opens in Europe
This new clinical trial will be available to children in 40 hospitals across 11 European countries and has been jointly funded by Solving Kids’ Cancer UK and the French charity, Imagine for Margo.
Solving Kids' CancerUK receives £21,114 from GamesAid
Solving Kids' Cancer UK thanks GamesAid – the UK video games industry based charity – for their important and generous support in 2019.
Solving Kids’ Cancer UK grant to Professor John Anderson
Solving Kids’ Cancer is pleased to announce that it has awarded a grant of £250,000 to Professor John Anderson of UCL, to study preclinical refinements of treatment of neuroblastoma with CAR-T cells.
